medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China

Ruijie Ling[1#], Yihan Yu[1*], Jiayu He[2], Jixian Zhang[1], Sha Xu[1], Renrong Sun[1], Wangcai Zhu[1], Mingfeng Chen[2], Tao Li[2], Honglong Ji[3], Huanqiang Wang[2]

#These authors contributed equally to this work.

1. Hubei Provincial Hospital of Integrated Chinese & Western Medicine, Wuhan, Hubei, China.

2. National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing, China.

3. Department of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.

Corresponding authors: Huan-Qiang Wang, Ph.D. National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, 29 Nanwei Road,Xicheng District, Beijing, 100010, China; E-mail: wanghq@niohp.chinacdc.cn; Hong-Long Ji, Ph.D. Department of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA; E-mail: James.ji@uthct.edu; Tao Li, M.D. National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing, China; E-mail: litao@niohp.chinacdc.cn.

Abstract

Background: The seroprevalence of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be a more reliable approach to detect true infected population, particularly in asymptomatic persons. The seroprevalence of IgG or IgM in people in general has not been well described. We choose a general hospital in Jianghan District in Wuhan, near the Huanan Seafood Wholesale Market, the epicenter of the COVID-19 pandemic in China, to conduct a serological survey, aimed at assessing asymptomatic infections of COVID-19 compared to epidemiological characteristics of people in Wuhan.

Methods*:* We conducted a serological survey of asymptomatic people who were tested in the general hospital using a validated colloidal gold method for IgM and IgG antibodies against SARS-CoV-2. Demographic, clinical, laboratory data and CT imaging findings from March 25 to April 28, 2020 were collected and compared. A total of 18,712 people mainly met the inclusion criteria to be enrolled (89.4%), with a median age of 40 years (range 4–81 years old), including 11,391 males (60.9%) with a median age of 42 years and 7,321 females (39.1%) with a median age of 37 years. The seroprevalence was estimated adjusting for imperfect diagnostic tests and the demographic structure of the population.

Results: During the period from 25 March 2020 to 28 April 2020, the seroprevalence of IgG and IgM standardized for age and sex in Wuhan varied between 7.67% and 1.56% for IgG, and between 0.71% and 0.16% for IgM, and showed a downward trend. No significant correlation was observed between the

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

seroprevalence of IgG and the different age groups, although none of the 26 individuals under the age of 19 years tested positive for IgG. The seroprevalence of IgM in different age groups was correlated with age (x^2 = 18.496, p= 0.035), with no IgM positivity detected under the age of 24 years old (n = 679). Accounting for test performance and adjusting for the age and sex of the general population, the seroprevalence of IgG and /or IgM was estimated at 2.72% (95% confidence interval [CI]: 2.49–2.95%), with a seroprevalence of 2.05% (1.79–2.31%) for males and 3.41% (2.99–3.83%) for females. The seroprevalence was significantly higher for females than males (x^2 = 35.702, $p < 0.001$), with an odds ratio of 1.36 (95% CI: 1.24–1.48). Based on the census number of the Wuhan population aged 4–81 years old in 2017, using IgG and/or IgM seroprevalence tests, the number of asymptomatic COVID-19-positive individuals aged 4–81 years old was estimated at 217,332 (95% CI: 198,709–235,955) in Wuhan from March 25 to April 28, 2020.

A significant difference was seen in the seroprevalence of IgG among people from different geographic areas and different types of workplaces (respectively, x^2 = 42.871, $p < 0.001$ and x^2 = 202.43, $p < 0.001$). Sixty percent of antibody-positive cases came from the top ten work units out of a total of 154 units. Some professions had a higher risk for positive antibody tests. From CT imaging of 1636 participants, the IgG antibody-positive cases had a greater number of abnormalities in CT imaging than IgG-negative cases (30.7% vs 19.7%). Significant differences were seen between test groups of antibody-positive and negative cases of IgG and /or IgM in the percentage of leucocytes, neutrophilic granulocytes and monocytes.

Conclusions: The reported number of confirmed patients in Wuhan only represents a small proportion of the total number of infections, and most of the Wuhan population remains susceptible to COVID-19. There were differences in IgG seroprevalence among geographic areas, which were consistent with the spread of the SARS-CoV-2 coronavirus in Wuhan. There was a significant aggregation of asymptomatic infections in individuals from some occupations, and based on CT and laboratory findings, some damage may have occurred in asymptomatic individuals positive for IgG antibody.

Keywords: COVID-19; SARS-CoV-2; serological testing; IgG; IgM; seroprevalence; computed tomography

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Introduction

Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a pandemic that has spread around the globe in the early months of 2020 [1-2]. As of May 17, 2020, COVID-19 infections occurred globally at more than 4,657,000 human cases and resulted in more than 312,000 human deaths according to Johns Hopkins University [3]. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis for SARS-CoV-2 is the gold standard for COVID-19 diagnosis [4-5]. However, epidemiological surveillance of confirmed COVID-19 cases captures only a portion of all infections because the clinical spectrum of SARS-CoV-2 infection ranges from mild to the onset of severe acute respiratory distress syndrome [6]. Many patients can be asymptomatic, greatly increasing the uncertainty of diagnosis [7]. We know that SARS-CoV-2-specific antibodies appear around 3–10 days after infection, with IgM appearing first and IgG following around 14 days after infection [8]. Even after the symptoms of infection disappear, IgG can still show seropositivity [9]. Therefore, SARS-CoV-2 serological assays are a good supplementary method to verify nucleic acid detection [10].

A series of serological surveys of SARS-CoV-2 have been reported [11-23]. However, many of them are small or based on non-random sampling of participants, some of them focusing on health-care workers or blood donors, and thus cannot provide precise estimates of seroprevalence by age group in the general population [24]. Additionally, most of these studies do not take into account the sensitivity or specificity of the antibody tests, or do not adjust for the age and sex of the general population, which decreases the accuracy of the estimation. Finally, almost none of these studies have described chest computed tomographic (CT) scan or laboratory findings in asymptomatic people.

The COVID-19 outbreak was first reported in the city of Wuhan, Hubei Province, China [25]. As Wuhan accepted the timely prevention strategies of lockdown for curbing population flow, it effectively controlled the spread of the pandemic. After 76 days of lockdown in Wuhan, the city reopened again on April 8, 2020. The residents have been allowed to resume working since that day if they met a set of COVID-19-associated tests, including SARS-CoV-2 nucleic acid tests (NAT) of nasopharyngeal swabs, chest CT scans or a SARS-CoV-2-specific serological test [26-27]. Serological surveys are the best tool to determine the spread of an infectious disease, particularly in the presence of asymptomatic cases [28]. These tests provide a unique opportunity to study the number of SARS-CoV-2 infections in the asymptomatic general population.

We choose a general hospital in Jianghan District near the Huanan Seafood Wholesale Market to conduct a serological survey of those people resuming work and other inhabitants in Wuhan using a validated assay for IgM and IgG antibodies against SARS-CoV-2. We chose this area because the Jianghan District was the early epicenter of the COVID-19 outbreak in China and many of the earliest COVID-19 cases were linked to the Huanan Seafood Wholesale Market in the same district of Wuhan [29]. We selected a serology test that has been fully validated using serum from confirmed COVID-19-infected individuals and well-characterized reference samples. In this study, we analyzed 18,721 medical examination records at this hospital including IgM and IgG tests for SARS-CoV-2 antibodies and other tests from March 25 to April 28, 2020. More than half of the individuals came from the Jianghan District,

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

while others came from different urban and rural areas and different populations in Wuhan. All of them were healthy people with no fever, headache or other symptoms of COVID-19. We aimed to estimate the seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, taking into account test performance and adjusting for the age and sex of Wuhan's population. We also describe the epidemiological characteristics of seroprevalence in its geographic and occupational distribution, as well as chest CT scan and laboratory findings from asymptomatic people. We hope this study will provide a reference for estimating the number of asymptomatic cases of COVID-19 and will improve our understanding of the epidemiology of the outbreak and the development of immunity to COVID-19 in general populations.

Methods

Subjects for Serology Testing

Population screening for IgG and IgM against SARS-CoV-2 was initiated on March 25 and was open to all residents of Wuhan who were symptom-free (**Supplementary materials Figure S1**). Most of them had returned to work, but a few of them had contact with infected persons who were asymptomatic visiting the designated hospital for COVID-19 diagnosing. The screening and sample collection were carried out in the hospital; hence, the majority of participants resided in the central districts of Wuhan. This was a cross-sectional, retrospective study to investigate seroprevalence in asymptomatic COVID-19 people in Wuhan for medical examinations. All people lived in Wuhan since the city went into lockdown starting January 22, 2020.

Subject selection criteria: All ages with no fever, headache or other symptoms of COVID-19 in whom specific IgG and IgM antibodies against SARS-CoV-2 were detected. Exclusion criteria: No specific test for SARS-CoV-2 antibodies was completed or clinical data was incomplete. From March 25 to April 28, 2020, 20,929 people visited the hospital for 21,526 medical examinations, of which 2,637 were excluded for lack of antibody testing. There were 18,889 medical examinations that were tested for antibodies with 498 re-examinations. A total of 17,923 people received NAT, with one patient suspected as nucleic acid-positive who was positive for IgG antibodies and negative for IgM antibodies. Among the 789 people without NAT, 10 (1.3%) were positive by antibody tests and the rest were negative (98.7%). A total of 18,712 (89.4%) people met the inclusion criteria with a median age of 40 years (range 4–81 years old), including 11,391 males (60.9%) with a median age of 42 years and 7,321 females (39.1%) with a median age of 37 years.

Data Collection

Clinical data were collected from March 25 to April 28, 2020, including birth date, sex, occupation, residential district, date of test, serum IgG positivity and IgM positivity or negative results for SARS-CoV-2 antibodies, nucleic acid testing, clinical symptoms, chest CT and laboratory tests. Only 1636 of the subjects had chest CT and 12481 subjects had the laboratory tests. SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA (Tangshan, registration certificate for the

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

medical devices of Peoples Republic of China: 20203400177) [30]. All enrolled medical examiners collected 2 ml peripheral venous blood. After centrifugation, serum was taken for SARS-CoV-2-specific IgG and IgM antibody detection within 2 h. Nasopharyngeal or oropharyngeal swabs used for SARS-CoV-2 nucleic acid testing were collected by trained and qualified medical staff to perform NAT within 2 h. The automatic nucleic acid extraction instrument was provided by the Hangzhou Allsheng Instruments Co. Ltd. (Allsheng). The ABI-7500 fluorescence PCR instrument was from Thermo Fisher Scientific Inc. All operations were carried out according to kit instructions.

Serology Test Validation

Before starting the screening for antibodies against SARS-CoV-2, we validated the serological assay with serum samples from 105 patients with COVID-19 confirmed by a SARS-CoV-2 fluorescent PCR kit with nasopharyngeal swabs collected between January 18 and February 22, 2020 [30]. The SARS-CoV-2 fluorescent PCR kits were provided by the DAAN Gene Co., Ltd. of Sun Yat-sen University (Registration certificate for medical device of Peoples Republic of China: 20203400060). In the validation test, the serological test showed a sensitivity of 86.7% (91 of 105) for IgG and 76.2% (80 of 105) for IgM antibodies. The detection sensitivity was 89.5% (94 of 105) for IgG and/or IgM antibodies. Second, we conducted the assay using serum samples collected from 138 health workers and 64 people with respiratory symptoms, without SARS-CoV-2. The serological test showed a specificity of 98.0% (198 of 202) for IgG and 99.0% (200 of 202) for IgM antibodies. The detection specificity was 99.0% (200 of 202) for IgG and/or IgM antibodies.

Current methods for measuring serum IgM and IgG mainly include enzyme-linked immunosorbent assays, chemiluminescence enzyme immunoassays, lateral flow immunoassays (LFIAs) and fluorescence immunoassays. LFIA specificity can reach about 99% with sensitivity from 80% to 86% [31]. Combined IgG and IgM tests have been shown to be better choices for sensitivity than measuring either antibody type alone. In our study, the LFIA method had a similar sensitivity and specificity for detecting SARS-CoV-2-specific antibodies.

CT Image Acquisition and Interpretation

All CT scans were obtained by a GE Optima CT660, Revolution CT. Scans were from the level of the thoracic entrance to the inferior level of the costophrenic angle with patients in a supine, head-first position, holding their breath. Parameters were slice thickness 5 mm, tube voltage 120 kV. Tube current was adjusted by an automatic exposure control system (GE Healthcare). Reconstructed CT images were transmitted to a workstation and picture archiving and communication systems (PACS) for multiplanar reconstruction post-processing. All CT images were independently reviewed by two experienced thoracic radiologists (Wang-cai Zhu and Ren-rong Sun) with over 10 years experience in thoracic radiology at Hubei Provincial Hospital of Integrated Chinese & Western Medicine. They independently evaluated initial CT images blinded to patients' clinical or laboratory results. The main CT features were analyzed and recorded including lesion distribution, morphology and number of lesions; major signs included pure ground-glass opacity (GGO), pure consolidation, GGO with consolidation, crazy-paving pattern,

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

interstitial lung disease (ILD) and other abnormalities.

Statistical analysis

All analyses were conducted using SPSS software (version 22.0, IBM Corporation, Armonk, NY, USA), the R software package (version 3.6.2; 2019, The R Foundation for Statistical Computing), and GraphPad Prism (Version 8.0, GraphPad Software, LLC, La Jolla, CA, USA). Proportions for categorical variables were compared either by Pearson Chi-square test or by Fisher's Exact Test. This study estimated the seroprevalence of IgM and IgG with 95% confidence interval (CI). Statistical analysis of continuous variables utilized means with standard deviation (SD) for normally distributed data and medians with interquartile range (IQR) for non-normally distributed data. Means for continuous variables were compared via independent group *t*-tests when the data were normally distributed; otherwise, the Mann-Whitney test was used. $P < 0.05$ was considered statistically significant.

To correct for the effects of gender and age, the seroprevalence of IgM positivity, IgG positivity, and IgM and/or IgG positivity were standardized according to the gender and age-specific population of Wuhan in 2017 (**Supplementary materials Table S1**) [19]. To correct for effects from accuracy of the serum antibody test, seroprevalence was corrected according to the sensitivity and specificity of the colloidal gold test in previous studies following the Rogan and Gladen method [32].

For comparisons of seroprevalence between different demographic groups (sex and age), geographic areas and occupations between subgroups, we used the likelihood ratio method and logistic regression to estimate 95% confidence intervals of odds ratios. In the logistic regression, we used the testing status of antibody (IgG+ or IgM+) against SARS-CoV-2 as the response and included the variable assessed as a covariate.

Ethics

This study was approved by the Ethics Committee of the Hubei Provincial Hospital of Integrated Chinese & Western Medicine (No. 2020011). Waiver of informed consent for collection of epidemiological data from individuals tested for COVID-19 was granted by the National Health Commission of China as part of the infectious disease outbreak investigation. All identifiable personal information was removed for privacy protection when data were extracted.

Results

Characteristics of Individuals Studied

Between March 26 and April 28, 2020, we enrolled a total of 18,721 asymptomatic participants, most of them from 154 work units in the central urban area of Wuhan, with a demographic distribution a little different from that of Wuhan (**Supplementary materials Figure S2**). The proportion of individuals under 19 and over 65 enrolled in the study was much smaller than the general population. Among those enrolled, 11, 391 (60.9%) were male and 7,321 (39.1%) were female. The median age of

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

the subjects was 40.0 years (IQR, 42–50; range, 4–81), with the majority (n = 17,367, 92.8%) aged 25 to 59 years. The cumulative count of the population tested for antibodies against SARS-CoV-2 and the number of positive cases of IgG and IgM are shown in **Figure 1**.

Seroprevalence Adjusting for Age, Sex and Test

Table 1 shows the unadjusted and adjusted seroprevalence for IgG and IgM against SARS-CoV-2 in asymptomatic people by sex. The unadjusted seroprevalence of IgG in females was higher than in males and was significantly different ($x^2 = 6.525$, $p = 0.011$), resulting in an odds ratio of 1.23 (95% CI: 1.05–1.45). The unadjusted seroprevalence of IgM in females was slightly higher than in males, but was not significantly different ($x^2 = 0.225$, $p = 0.635$). When IgG and IgM positivity were analyzed together, the unadjusted seroprevalence of IgG and /or IgM in females was still higher than in males and was significantly different ($x^2 = 7.191$, $p = 0.007$), producing an odds ratio of 1.09 (95% CI: 1.02–1.17).

After standardization according to the number of people of different ages and sex in the population of Wuhan from the national census of 2017, the age- and gender-adjusted seroprevalence of IgG was higher in females than in males and the difference was significant ($x^2 = 20.433$, $p < 0.001$), with an odds ratio of 1.24 (95% CI: 1.14–1.36). There was no significant difference in IgM between females and males ($x^2 = 2.436$, $p = 0.119$). The age- and sex-adjusted seroprevalence of IgG and /or IgM was still higher in females than in males, and the difference was significant ($x^2 = 21.906$, $p < 0.001$), with an odds ratio of 1.25 (95% CI: 1.14–1.36).

However, after adjusting for age and sex, and adjusting for test performance (sensitivity and specificity), the overall adjusted serum positive rate for IgG antibodies was 1.67% (95% CI: 1.49–1.85), 1.02% (0.84–1.20) for males and 2.35% (2.00–2.70) for females, and the seroprevalence was significantly higher for females than males ($x^2 = 52.104$, $p < 0.001$), as shown by an odds ratio of 1.54 (95% CI: 1.40–1.70). After similar adjustments, the overall adjusted serum positive rate for IgG and /or IgM antibodies was 2.72% (95% CI: 2.49–2.95), 2.05% (1.79–2.31) for males and 3.41% (2.99–3.83) for females, and the seroprevalence was significantly higher for females than males ($x^2 = 35.702$, $p < 0.001$) at an odds ratio of 1.36 (95% CI: 1.24–1.48). The census indicated that the Wuhan population aged 4–81 years in 2017 was 7,990,158. Based on this number, asymptomatic COVID-19-positive individuals aged 4-81 years, using IgG and/or IgM seroprevalence tests, were estimated at 217,332 (95% CI: 198,709–235,955) in Wuhan from March 25 to April 28, 2020.

Distributions in Time Series and Ages

Table 2 shows the demographic characteristics and seroprevalence of IgG and the odds ratio arranged by time series. In the first five days, we estimated the seroprevalence of IgG at 3.82% (95% CI 2.18–5.47, n = 523). The estimate increased to 5.14% (4.08–6.19, n = 1694) in the second five days, to 8.43% (6.87–9.99, n = 1222) in the third five days, and then decreased to 3.58% (3.01–4.16, n = 4046) in the fourth five days, to 2.79% (2.40–3.19, n = 6695) in the fifth five days, to 2.21% (1.64–2.78, n = 2534) in the sixth five days, and finally to 1.45% (0.93–1.98, n = 1998) in the seventh five day period. The positivity for IgM over the same time frame declined slightly and remained at a low level, with the highest rate at 1.33% (0.35–2.32) in the first five days, which dropped to a low of 0.28% (0.07–0.48) in

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

the sixth five day period (**Supplementary materials Table S2**).

The distribution of the adjusted seroprevalence of IgG and IgM in the time series, and the distribution of the crude seroprevalence of IgG and IgM in different age groups are in **Figure 2**. The seroprevalence of IgG or IgM in different testing time periods was correlated with the time periods ($x^2 = 153.88$, $p < 0.001$; $x^2 = 17.075$, $p = 0{\cdot}009$). Although none of the 26 individuals under the age of 19 years tested positive for IgG, no significant correlation was observed between the seroprevalence of IgG and the different age groups ($x^2 = 11.541$, $p = 0.292$). In contrast, the seroprevalence of IgM in different age groups was correlated with age ($x^2 = 18.496$, $p = 0.035$), showing a higher seroprevalence of IgM in the middle-aged group for men and an increased seroprevalence with age for women. No IgM positivity was detected in males or females under 24 years old. The positivity for IgM antibodies in males over 55 years old was significantly lower than for females.

Geographic and Occupational Distribution of Seroprevalence

Among the 154 work units, 57.8% (89/154) of work units had at least one positive case of IgG or IgM among employees, accounting for 92.5% (17,315/18,712) of individuals receiving serology testing, including in-service and partly retired employees. Approximately 60% of antibody-positive cases came from the top ten work units having the most number of cases (6.5%, 10/154), including a securities and insurance hall located in Jianghan District with a higher risk for positive cases at 31.0% (9/29), a law firm located in Jiangan District with positive rate of 27.4% (31/113), an urban construction company located in Jianghan District with positive rate of 17.7% (6/34), and rural commercial banks with a positive rate of 7.7% (34/444)). In particular, there was a bank branch with a positive rate of 15.3% (15/98) and two community health service centers with positive rates of 5.06% (9/178), all of them located in Jianghan District. In contrast, there were no positive cases found in serology tests of over 220 individuals from five other community health service centers located far from the central urban area of Wuhan. There were three work units which contributed 30.3% (199/657) of the number of antibody-positive individuals, including a water supply company, a real estate company located in Jianghan District, and telecommunications companies located in Jianghan District.

The crude seroprevalence and odds ratio by geographic areas from different types of workplaces are shown in **Table 3** and **Table 4**. A significant difference was seen in seroprevalence of IgG by urban area ($x^2 = 42.871$, $p < 0.001$), but no significant difference was observed for IgM ($x^2 = 14.729$, $p = 0.069$). The Wuchang and Jianghan districts had higher seroprevalence of IgG than other urban areas. **Figure 3** shows the geographic distribution of the seroprevalence of IgG or IgM antibody against SARS-CoV-2 in asymptomatic people from March 25 to April 28, 2020, in Wuhan, China.

A significant difference was seen in the seroprevalence of IgG and IgM among people from different work units ($x^2 = 202.43$, $p < 0.001$ for IgG; $x^2 = 28.915$, $p = 0.001$ for IgM). Among the tested individuals, the seroprevalence of IgG was highest for those who voluntarily came for serology test by themselves, followed by those encouraged by their work units, including real estate property companies, urban construction companies, telecommunications companies, banks, securities and insurance companies, law firms, and procuratorates.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

CT Imaging Findings

The relationship between abnormal chest CT imaging and the seroprevalence of IgG and IgM antibodies for different age groups is shown in (**Supplementary materials Figure S3 and Figure S4**). Of the participants, 1636 underwent chest CT, and 342 had abnormal images. CT imaging abnormality was 30.7% (94/306) for people who were IgG antibody-positive compared to 19.7% (262/1330) for those who were IgG negative. The difference was significant ($x^2 = 17.743$, $p < 0.001$), as shown by the odds ratio of 1.13 (95% CI: 1.06–1.21).

Among the IgG-positive patients, typical abnormal chest CT signs were GGOs, GGOs with small mixed consolidation, and prominent peripheral subpleural distribution. Lesions mostly involved both lungs. Some were accompanied by smooth interlobular septal thickening, and some were subpleural lines of small nodules with increased density. **Figure 4** shows the different levels in the lungs of one asymptomatic individual who was positive for IgG.

Laboratory Findings

Laboratory hematology results for the asymptomatic individuals are shown in **Table 5**. A total of 12,481 (65.7%) had blood samples analyzed simultaneously for routine cytology. Significant differences were seen between IgG and/or IgM-positive test groups in leucocytes, neutrophilic granulocytes and monocyte percentage. Leucocytes and neutrophilic granulocytes decreased, while the monocyte percentage increased for people who were IgG/IgM-positive compared to negative individuals. Gender stratification analysis showed significant differences in the results of these indicators between positive and negative males, but no difference was found between females.

Discussion

Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infections is critical for understanding the overall prevalence and infection potential of COVID-19 [10]. There were some SARS-CoV-2 seroprevalence studies of target people earlier this year. In Denmark, 9,496 blood donors (17–69 years old) who gave blood during April 6–17, 2020 showed seroprevalence of IgM and IgG antibodies at 1.7% (0.9–2.3%), adjusted for assay sensitivity and specificity, which differed by region [22]. A similar cross-sectional study conducted in Japan showed an IgG seroprevalence of 3.3% (2.3–4.6%) using 1,000 samples from patients at outpatient settings [21]. Recently, there have been some SARS-CoV-2 seroprevalence studies from cohorts representing the general population of China [11-13], the USA [14], Switzerland [15] and Spain [16]. The study from China showed the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts, which included 714 healthcare workers, 346 hotel staff members and 219 family members of the healthcare workers. A community seroprevalence study in Los Angeles County showed the prevalence of antibodies to SARS-CoV-2 at 4.65% in 863 adults. The Switzerland study showed seroprevalences from 4.8% to 10.9% in different weeks in Geneva, which included 2766 participants and 1339 households. The Spanish study including 60,000 participants showed a nationwide seroprevalence of 5.0% (4.7–5.4%), with urban areas around Madrid exceeding 10%. All of these studies demonstrate that most of the population appears to have remained unexposed to SARS-CoV-2.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Our study aimed to estimate the seroprevalence from SARS-CoV-2 infections in Wuhan, the epicenter of the COVID-19 pandemic in China. Despite being the earliest area to be affected by COVID-19, the seroprevalence among the general population was only 3.35%. Accounting for the test performance and adjusting for the age and sex of the general population, we estimated the seroprevalence of IgG and IgM in 18,712 individuals aged 4–81 years from different geographic areas and different occupations in the city during the period from March 25 to April 28, 2020. Our study indicates that most of the Wuhan population remains susceptible to COVID-19. There were 50,333 reported confirmed patients up to April 28 in Wuhan, and we estimate that for every reported confirmed case, there were at least 4.1 (204,548/50,333) asymptomatic infections in the general population. This is smaller than the estimate of the Switzerland study, which estimated 11.6 infections in the community for every reported confirmed case. Our estimate in accordance with data from a detailed surveillance study by the Chinese Center for Disease Control and Prevention, which indicated that 80% of confirmed cases were mild, and a number of patients can remain asymptomatic with very low symptomatology [330]. Thus, epidemiological studies of asymptomatic infections should receive sufficient attention.

Our study showed there were differences in IgG seroprevalence among urban and rural areas, which were much higher in Wuchang District and Jianghan District than in other areas. Based on the cumulative number of reported cases of COVID-19 from March 25 to April 28, and the number of residents in each district in Wuhan, we estimated an average incidence rate per 100,000 people of 2.98% (95% CI: 2.97–2.99) during this period. Incidence rates were higher in the Jianghan and Wuchang districts, at 8.09% (95% CI: 8.02–8.15) and 7.25% (95% CI: 7.20–7.29) per 100,000 people, respectively, which show that seropositive rates in different geographic areas were consistent with the spread of the SARS-CoV-2 coronavirus in Wuhan (**Supplementary materials Table S3 and Figure S5**).

In our study, the highest seroprevalence of IgG was in those people who voluntarily came for serology testing by themselves, most of whom had close contacts with COVID-19 patients and therefore had a higher risk of infection. Our study found significant aggregation of asymptomatic infections in individuals from certain occupations. The groups in some industries with high IgG seroprevalence were easy to identify due to the nature of their jobs, such as insurance and securities professionals, professionals in the law industry, maintenance personnel of urban construction company, and staff of rural commercial banks located in the higher risk districts. It is known that some staff undertook substantial voluntary work in response to government calls during the COVID-19 pandemic, to assist in, for instance, administering in the local residential communities, transporting COVID-19 patients, and screening the general population for epidemic incidence. Thus, they faced a greater chance of contacting infected people during their work, and were more likely to be infected, even with personal protection.

Some studies found an average level of IgG antibodies higher in females than in males [34]. In our study, the IgG seroprevalence was also higher in females than in males, indicating that females were more likely to have asymptomatic infections. However, there was no significant correlation observed between the seroprevalence of IgG and different age groups.

To our knowledge, CT examination is of great importance for the early detection and treatment of

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

patients affected by COVID-19, and the most common CT features in patients affected by COVID-19 include GGO and consolidation involving the bilateral lungs in a peripheral distribution [35]. The parameters for peripheral blood cells in patients with COVID-19 are significantly abnormal, with the most obvious being a decrease in the number of lymphocytes [36]. In our study, CT imaging and laboratory results demonstrated similar differences between IgG antibody-positive and negative individuals, which is a reminder that some damage may have occurred in some asymptomatic individuals positive for IgG antibodies.

This study had a few limitations. First, this study had selection bias since the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses. Therefore, the sample was incompletely randomized and insufficiently representative, compromising the assessment accuracy of the prevalence of asymptomatic infections in Wuhan. Second, as the examinees were only from the back-to-work population, people under the age of 19 and over age 65 were too few to be fully covered in analyses.

This study has the important feature of having been designed as repeated five-day serosurveys, which allowed for the monitoring of seroprevalence progression just after the end of the first epidemic. Further, our study applied scientific statistical methods accounting for the demographic structure of the general population and imperfect diagnostic tests to estimate seroprevalence in the overall population, while capturing uncertainty in the estimates. Our study will provide useful information for the investigation of herd immunity and help design targeted strategies for prevention.

Conclusions

The seroprevalence of IgG and IgM in Wuhan indicates that reported confirmed patients only represent a small proportion of the total number of infections, and most of the Wuhan population remains susceptible to COVID-19. There were differences in IgG seroprevalence among geographic areas, which were consistent with the spread of the SARS-CoV-2 coronavirus in Wuhan. Our study found significant aggregation of asymptomatic infections in individual from certain occupations. The CT imaging and laboratory tests suggest that some slight damage may have occurred in some asymptomatic individuals positive for IgG antibodies.

Abbreviations

COVID-19: coronavirus disease 2019; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; IgM: immunoglobulin M; IgG: immunoglobulin G; RT-PCR: reverse transcription-polymerase chain reaction; NAT: nucleic acid test; GGO: ground-glass opacity; ILD: interstitial lung disease; CT: computed tomography; PACS: picture archiving and communication systems; IQR: interquartile range; CI: confidence interval.

Supplementary Material

Supplementary figures and tables.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

http://www.thon.org/v .pdf

Acknowledgments

We acknowledge the work and contribution of all the health care 0providers from the Hubei Provincial Hospital of Integrated Chinese & Western Medicine. This study was supported with funding from the Advisory Research Project of the Chinese Academy of Engineering in 2019 (2019-XZ-70).

Author Contributors

RJL, YHY, HQW and TL were responsible for study design. RJL, YHY, HQW and JYH were responsible for the literature search. RJ, YHY, JXZ, SX, RRS, WCZ, HQW and MFC were responsible for data collection. HQW was responsible for data analysis. HQW and MFC were responsible for figures. HQW, HLJ and TL were responsible for data interpretation. HQW, HLJ and JYH were responsible for writing the first draft of the manuscript. All authors contributed to the final draft.

Funding

This work was supported by Advisory Research Project of the Chinese Academy of Engineering in 2019 (2019-XZ-70). The funders had no role in study design, data collection, data analysis, interpretation or writing of the report.

Competing Interests

The authors declare that no competing interest exists.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 1. Cumulative count of asymptomatic individuals positive for antibodies against SARS-CoV-2 in a hospital in Wuhan, China, 2020. A: A total of 18,712 asymptomatic individuals tested positive for IgG or IgM antibodies against SARS-CoV-2 from March 25 to April 28, 2020. B: A total of 627 asymptomatic individuals tested positive for serum IgG antibodies, including 351 males and 276 females, from March 25 to April 28, 2020. C: A total of 89 asymptomatic individuals tested positive for serum IgM antibodies, including 52 males and 37 females, from March 25 to April 28, 2020.

Table 1. Seroprevalence of IgG, IgM and IgG/IgM in asymptomatic individuals by sex (%, 95% CI)

	N	n_1	IgG^+			n_2	IgM^+		n_3	IgG^+ or IgM^+		
			Unadjusted	Ages and genders adjusted	Assay adjusted		Unadjusted	Ages and genders adjusted		Unadjusted	Ages and genders adjusted	Assay adjusted
Male	11391	351	3.08(2.76~3.40)	2.58(2.29~2.87)	1.02(0.84~1.20)	52	0.46(0.34~0.58)	0.30(0.20~0.40)	367	3.22(2.90~3.54)	2.67(2.37~2.97)	2.05(1.79~2.31)
Female	7321	276	3.77(3.33~4.21)	3.74(3.31~4.17)	2.35(2.00~2.70)	37	0.51(0.35~0.67)	0.44(0.29~0.59)	290	3.96(3.51~4.41)	3.89(3.45~4.33)	3.41(2.99~3.83)
Average	18712	627	3.35(3.09~3.61)	3.15(2.90~3.40)	1.67(1.49~1.85)	89	0.48(0.38~0.58)	0.37(0.28~0.46)	657	3.51(3.25~3.77)	3.27(3.02~3.52)	2.72(2.49~2.95)

N is the total number of individuals, n_1 is the number of IgG-positive individuals, n_2 is the number of IgM-positive individuals, n_3 is the number of IgG-positive or IgM-positive. IgG^+ is IgG antibody positivity, IgM^+ is IgM antibody positivity, IgG^+ or Ig^+ is IgG antibody positivity or IgM antibody positivity.

Assay adjusted is the adjusted rate of IgG antibody positivity, IgM antibody positivity, IgG antibody positivity or IgM antibody positivity, corrected for sensitivity and specificity of the colloidal gold test in previous studies following the Rogan Gladen methods, to correct for effects from accuracy of the serum antibody test. According to the Rogan Gladen methods, $P=(t+\beta-1)/(\alpha+\beta-1)$, in which P is adjusted seroprevalence, α is sensitivity of the antibody test (colloidal gold method), β is specificity of the antibody test by colloidal gold method, t is age- and gender-adjusted seroprevalence or positive test frequency.

Table 2. Demographic characteristics and seroprevalence of IgG in asymptomatic individuals and odds ratio by time series.

Five-day period		Male, %	Median age in years (IQR)	Crude seroprevalence of IgG	Adjusted seroprevalence of IgG	Crude relative risk (95% CI)	P value	Odds ratio (95% CI) adjusting for age and sex	P value
1	523	55.7	38(30~48)	3.82(2.18~5.47)	2.98（1.52~4.44）	2.70(1.52~4.81)	0.001	2.62(1.47~4.68)	0.001
2	1694	70.3	40(32~51)	5.14(4.08~6.19)	4.18（3.23~5.13）	3.68(2.40~5.62)	<0.001	3.65(2.38~5.60)	<0.001
3	1222	55.3	40(31~51)	8.43(6.87~9.99)	7.67（6.18~9.16）	6.25(4.11~9.50)	<0.001	5.92(3.87~9.05)	<0.001
4	4046	61.0	40(31~50)	3.58(3.01~4.16)	3.18（2.64~3.72）	2.52(1.69~3.77)	<0.001	2.42(1.61~3.64)	<0.001
5	6695	60.9	40(33~49)	2.79(2.40~3.19)	2.18（1.83~2.53）	1.95(1.32~2.89)	0.001	1.89(1.27~2.82)	0.002
6	2534	64.0	41(31~51)	2.21(1.64~2.78)	1.56（1.08~2.04）	1.53(0.98~2.41)	0.064	1.49(0.94~2.36)	0.086
7	1998	55.2	32(27~42)	1.45(0.93~1.98)	2.23（1.58~2.88）	1(ref)	--	1(ref)	--

Note: N is number of individuals; IQR is interquartile range.



Figure 2. Distributions of seroprevalence of IgG and IgM in asymptomatic individuals in time series and age groups. A: The seroprevalence with 95% CI of IgG adjusted for age in male and female asymptomatic individuals from March 25 to April 28, 2020 in Wuhan, China. B: The seroprevalences with 95% CI of IgM adjusted for age in male and female asymptomatic individuals from March 25 to April 28, 2020 in Wuhan, China. C: The crude seroprevalence with 95% CI of IgG in male and female asymptomatic individuals from ages 4 to 81 in Wuhan, China. D: The crude seroprevalence with 95% CI of IgM in male and female asymptomatic individuals from ages 4 to 81 in Wuhan, China.

Table 3. Seroprevalence of IgG and IgM and odds ratio by geographic location (urban and rural areas)

Urban and rural areas	n	Male, %	Median age in years (IQR)	IgG+				IgM+			
				n_1	% (95% CI)	Odds ratio (95% CI)	P value	n_1	% (95% CI)	Odds ratio (95% CI)	P value
Jiangan	1468	56.1	43(33~51)	40	2.72(1.89~3.55)	1(ref)	--	3	0.20(0.00~0.43)	1(ref)	--
Jianghan	10667	60.2	41(33~51)	423	3.97(3.60~4.34)	1.50(1.08~2.08)	0.016	58	0.54(0.40~0.68)	2.76(0.86~8.83)	0.087
Huangpi	1808	53.7	31(26~36)	39	2.16(1.49~2.83)	0.86(0.55~1.35)	0.512	3	0.17(0.00~0.36)	1.08(0.22~5.44)	0.926
Hanyang	1515	75.6	46(34~53)	39	2.57(1.77~3.37)	0.98(0.62~1.53)	0.922	9	0.59(0.20~0.98)	2.97(0.80~11.0)	0.104
Qiaokou	974	78.1	37(30~44)	13	1.33(1.26~1.40)	0.53(0.28~1.00)	0.051	2	0.21(0.18~0.24)	1.22(0.20~7.34)	0.831
Wuchang	1580	59.2	43(32~51)	37	4.19(2.87~5.51)	1.59(1.01~2.51)	0.045	7	0.79(0.21~1.37)	4.04(1.04~15.7)	0.043
Hongshan	565	45.7	39(30~49)	14	2.48(1.20~3.76)	0.91(0.49~1.69)	0.767	4	0.71(0.02~1.40)	3.70(0.82~16.6)	0.088
Dongxihu	172	80.2	46(34~52)	4	2.33(0.08~4.58)	0.89(0.32~2.52)	0.829	2	1.16(0.00~2.76)	5.94(0.98~35.9)	0.053
Caidian and the others	87	72.4	39(33~47)	4	4.60(0.20~9.00)	1.84(0.64~5.26)	0.258	0	--	--	--
Outside	572	46.9	42(33~48)	14	2.45(1.18~3.72)	0.89(0.48~1.64)	0.704	1	0.17(0.00~0.51)	0.87(0.09~8.35)	0.901

Note: n is the total number of individuals; n_1 is the number of IgG-positive individuals; n_2 is the number of IgM-positive individuals; n_3 is the number of IgG-positive or IgM-positive individuals; IQR is interquartile range. Odds ratios were adjusted for age and sex. Jianghan district was the reference group to which other groups were compared.

Table 4. Odds ratios of the seroprevalence of IgG and IgM by occupation (types of work units)

Type of work unit	n	Male, %	Median age in years (IQR)	IgG+				IgM+			
				n_1	% （95% CI）	Odds ratio (95% CI)	P value	n_1	% （95% CI）	Odds ratio (95% CI)	P value
Primary medical care	628	33.9	43(34~50)	15	2.39(1.20~3.58)	1(ref)	--	3	0.48(0.00~1.02)	1(ref)	--
Tap water and natural gas	4961	65.6	42(35~50)	96	1.94(1.56~2.32)	0.87(0.50~1.51)	0.622	21	0.424(0.24~0.60)	0.97(0.29~3.29)	0.961
Real estate	2481	67	41(32~52)	147	5.93(5.00~6.86)	2.78(1.62~4.79)	<0.001	17	0.69(0.36~1.02)	1.56(0.45~5.37)	0.483
Government institutions	2401	66.4	44(35~52)	59	2.46(1.84~3.08)	1.09(0.61~1.94)	0.762	10	0.42(0.16~0.68)	0.92(0.25~3.37)	0.897
The airport	1800	53.5	31(26~36)	36	2.00(1.35~2.65)	1.01(0.54~1.86)	0.982	3	0.17(0.00~0.36)	0.50(0.10~2.53)	0.401
Banks, securities and insurance companies	1786	46.7	35(30~45)	89	4.98(3.97~5.99)	2.38(1.36~4.15)	0.002	17	0.95(0.50~1.40)	2.43(0.70~8.37)	0.161
Highway management and auto repair	944	76.3	47(35~54)	41	4.34(3.04~5.64)	1.99(1.09~3.65)	0.025	8	0.85(0.26~1.44)	1.87(0.49~7.17)	0.361
Telecommunications companies	750	45.2	35(31~40)	45	6.00(4.30~7.70)	2.96(1.63~5.38)	<0.001	1	0.13(0.00~0.39)	0.36(0.04~3.47)	0.375
Law firms, procuratorates	706	51.4	39(31~50)	40	5.67(3.96~7.38)	2.64(1.44~4.83)	0.002	2	0.28(0.00~0.67)	0.66(0.11~3.98)	0.652
Rehab	700	72.7	45(36~51)	15	2.14(1.07~3.21)	0.97(0.47~2.00)	0.925	5	0.71(0.09~1.33)	1.62(0.38~6.58)	0.514
Other service industries	1501	60.4	39(31~49)	33	2.20(1.46~2.94)	1.01(0.54~1.88)	0.978	1	0.07(0.00~0.20)	0.16(0.02~1.53)	0.112
Personal	54	61.1	42(32~49)	11	20.4(9.63~31.1)	11.5(4.95~26.6)	<0.001	1	1.85(0.00~5.44)	4.40(0.45~43.3)	0.204

Note: n is the total number of individuals; n_1 is the number of IgG-positive individuals; n_2 is the number of IgM-positive individuals; n_3 is the number of IgG-positive or IgM-positive individuals; IQR is interquartile range. Real estate includes real estate agencies, residential property management firms and urban construction corporations. Odds ratios were adjusted for age and sex. Primary medical care was the reference groups to which other groups were compared.





Figure 3. Geographic distribution of asymptomatic people in Wuhan. A: The geographic distribution of seroprevalences of IgG or IgM antibodies against SARS-CoV-2 in asymptomatic people from March 25 to April 28, 2020, in Wuhan, China. B: The geographic distribution of asymptomatic people estimated according to the seroprevalences and residential populations in the districts of Wuhan in 2017.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 4. CT imaging of one asymptomatic individual positive for IgG. A shows a platelet of GGO in the posterior segment of the upper lobe of the left lung. B shows GGOs with small mixed consolidation in the posterior basal segment of the lower lobe of both lungs, and the pleural offline was seen in the posterior basal segment of the lower lobe of the left lung.

Table 5. Laboratory hematology results of asymptomatic individuals.

Laboratory result	Normal range	All		IgG−/IgM−		IgG+/IgM+		*P*
		n	Mean (SD)	n1	Mean (SD)	n2	Mean (SD)	
Leucocytes, $\times 10^9$/L	3.5–9.5	12481	6.9 (1.8)	12037	6.9 (1.8)	444	6.7 (1.7)	0.027
Neutrophilic granulocyte, $\times 10^9$/L	1.8–6.3	12481	3.9 (1.3)	12037	3.9 (1.3)	444	3.8 (1.3)	0.027
Monocyte percentage, %	3.1–10.0	12481	7.4 (2.1)	12037	7.4 (2.1)	444	7.6 (2.1)	0.006

SD: Standard deviation

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. Purcell LN, Charles AG. An Invited Commentary on "World Health Organization declares global emergency: A review of the 2019 novel Coronavirus (COVID-19)": Emergency or new reality? Int J Surg. 2020;76:111.
2. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
3. [Internet] Johns Hopkins University. COVID-19 Case Tracker. 2020. Accessed 2 June 2020. https://coronavirus.jhu.edu/
4. [Internet] WHO. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, 17 March 2020. Accessed 2 June 2020. https://apps.who.int/iris/handle/10665/331656
5. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386-389.
6. Guan WJ, Ni ZY , Hu Y , Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720
7. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of internal medicine. 2020;172(9):577-82.
8. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;ciaa344.
9. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv. 2020.
10. Huaiyu T, Ottar NB. Population serology for SARS-CoV-2 is essential to regional and global preparedness. Lancet Microbe. 2020.
11. Wu X, Fu B, Chen L, Feng Y. Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China. J Med Virol. 2020;10.1002/jmv.25904.
12. Xin Xu, Jian Sun,Sheng Nie, Huiyuan Li, Yaozhong Kong, Min Liang, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nature Medicine. 2020.
13. To KKW, Cheng VCC, Cai JP, Chan KH, Chen LL, Wong LH, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microbe. 2020;3(1):111-118;
14. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-Specific antibodies among adults in Los Angeles County, California, on April 10–11, 2020. JAMA. 2020; 323(23):2425-2427.
15. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020; S0140-6736(20)31304-0.
16. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiméne A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500.
17. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. medRxiv. 2020.
18. Snoeck CJ, Vaillant M, Abdelrahman T , Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. medRxiv 2020.
19. Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208-211.
20. Shakiba M, Nazari SSH, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran. medRxiv. 2020.
21. Doi A, Kentaro I, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study. medRxiv. 2020.
22. Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-

medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132423; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis. 2020; ciaa849.

23. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med. 2020;382 (24):2302-2315.
24. Marina P, Beatriz PG, Roberto PB, Jesús O, Miguel AH, Mayte PO, et al.Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020; S0140-6736(20)31483-5.
25. Kraemer MUG, Yang C-H, Gutierrez B, Wu C-H, Klein B, Pigott DM, et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. medRxiv. 2020.
26. Liu R, Han H, Liu F, Lv Z, Wu K, Liu Y, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim Acta. 2020;505:172-175.
27. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020; 10.1002/jmv.25727.
28. Metcalf CJE, Farrar J, Cutts FT ,Basta, NE, Graham, AL, Lessler J, et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet. 2016; 388(10045):728-30.
29. Huang C, Wang Y, Li X, Ren L, Zhao J, Yi H, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.
30. Zhang W, Lu X, Huang C, Wei M, Li S, Peng H, et al. Clinical Evaluation and Application of Detection for SARS-CoV-2 IgM and IgG Antibodies with Colloidal Gold Immunochromatography Assay. Chinese Journal of Virology. 2020;36(03):348-354.
31. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. Diagnostics (Basel, Switzerland). 2020;10(5):319.
32. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71-6.
33. Response EWGfNE. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 2020; 41(2):145-51.
34. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender. J Med Virol. 2020;10.1002/jmv.25989.
35. Cuiping Bao, Xuehuan Liu, Han Zhang, Yiming Li, Jun Liu.Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis.J Am Coll Radiol. 2020;17(6):701-709.
36. Pan A, Liu L, Wang CL, Guo H, Hao XJ, Wang Q, et al. Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA. 2020;323(19):1915-1923.